Macquarie Group Ltd. decreased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) by 3.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,856 shares of the biotechnology company’s stock after selling 2,537 shares during the period. Macquarie Group Ltd.’s holdings in Iovance Biotherapeutics were worth $634,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of IOVA. Envestnet Asset Management Inc. lifted its position in Iovance Biotherapeutics by 17.6% during the first quarter. Envestnet Asset Management Inc. now owns 14,017 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 2,099 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of Iovance Biotherapeutics by 71.8% in the first quarter. Rice Hall James & Associates LLC now owns 1,085,121 shares of the biotechnology company’s stock worth $18,067,000 after buying an additional 453,337 shares during the last quarter. Raymond James & Associates raised its holdings in shares of Iovance Biotherapeutics by 53.3% in the first quarter. Raymond James & Associates now owns 15,386 shares of the biotechnology company’s stock worth $256,000 after buying an additional 5,350 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Iovance Biotherapeutics by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 1,772,007 shares of the biotechnology company’s stock worth $29,504,000 after buying an additional 104,913 shares during the last quarter. Finally, AlphaCrest Capital Management LLC raised its holdings in shares of Iovance Biotherapeutics by 11.7% in the first quarter. AlphaCrest Capital Management LLC now owns 17,538 shares of the biotechnology company’s stock worth $292,000 after buying an additional 1,838 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.
Insider Activity at Iovance Biotherapeutics
In other news, Director Merrill A. Mcpeak purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 21st. The shares were bought at an average price of $6.15 per share, for a total transaction of $61,500.00. Following the completion of the transaction, the director now owns 70,150 shares in the company, valued at $431,422.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Iovance Biotherapeutics Stock Performance
IOVA stock opened at $6.21 on Monday. The firm has a market cap of $1.39 billion, a PE ratio of -2.50 and a beta of 0.24. The firm’s fifty day moving average is $7.07 and its 200 day moving average is $8.06. Iovance Biotherapeutics, Inc. has a one year low of $5.42 and a one year high of $18.73.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($0.64) EPS for the quarter, meeting the consensus estimate of ($0.64). During the same quarter last year, the business posted ($0.63) EPS. Research analysts predict that Iovance Biotherapeutics, Inc. will post -2.82 earnings per share for the current fiscal year.
Iovance Biotherapeutics Profile
Iovance Biotherapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors.
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating).
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.